VPVictor Román Pimentel-Quiroz

Victor Román Pimentel-Quiroz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victor Román Pimentel-Quiroz has a total of 333 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC)

    by Konstantinos Triantafyllias, Ramiro Gomez, Jisna Paul, Simone Appenzeller, Elena Bartoloni, Alejandro Benitez, Daniel Brito de Araujo, Solciris A. Dominguez, Komal Ejaz, Antonis Fanouriakis, et al.

    Background: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases that include dermatomyositis, polymyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy in both adult and juvenile populations. Interstitial lung disease (ILD) is a common and serious complication of IIM, with a highly variable clinical course ranging from indolent disease to rapidly progressive respiratory failure, often influenced by underlying myositis-specific autoantibody profiles. Despite the substantial morbidity and mortality associated with IIM-ILD in both adults and children, high-quality evidence to guide clinical management remains limited. A major barrier to progress in this field is the lack of standardized disease nomenclature and uniform diagnostic or classification criteria, which hampers cohort development, limits comparability across studies, and restricts generalizability of findings. To address this gap, we will conduct a systematic review to inform a consensus-based disease definition for adult and juvenile IIM-ILD, with detailed methodology outlined in this protocol. This review will not evaluate prognosis, treatment, or clinical outcomes, but instead focus exclusively on how IIM-ILD is defined and operationalized across studies. Methods: Following PRISMA 2020 statement and Cochrane methodology, we will search PubMed, EMBASE, Scopus, Cochrane Systematic Reviews, and Cochrane Central from inception to June 30, 2025, using a ‘‘Peer Review of Electronic Search Strategies (PRESS)’’—validated strategy. Eligible studies will include randomized controlled trials (RCTs), cohort and case–control studies, systematic reviews, meta-analyses, guidelines, and consensus statements explicitly reporting IIM-ILD definitions in human participants of all ages. Study selection will be performed in Covidence using predefined criteria. Data extraction will capture case definitions, classification criteria, diagnostic methods, ILD patterns, autoantibody profiles, and study characteristics. Quantitative synthesis will summarize the frequency and components of definitions where possible; otherwise, a structured narrative synthesis will be performed. Discussion: Our systematic review protocol is the first comprehensive attempt at synthesizing the highly heterogenous disease nomenclature currently employed in adult and juvenile IIM-ILD literature. Findings will map areas of agreement and inconsistency in existing definitions, forming an evidence base for subsequent consensus processes, such as Delphi, to establish standardized nomenclature. Harmonized definitions are expected to improve research reproducibility, facilitate multicentric collaboration, and improve patient stratification in clinical practice and trials. Systematic review registration: PROSPERO ID: 1129967.

  • Factors associated with changes in self-efficacy in patients with systemic lupus erythematosus. Data from the almenara lupus cohort

    by Alvaro M. Ñaña-Cordova, Zulema Mamani-Condori, Itala Jordan-Beisaga, Valeria L. Reyna-Ruiz, Rocío V. Gamboa-Cardenas, Victor Pimentel-Quiroz, Cristina Reátegui-Sokolova, Samira García-Hirsh, Zoila Rodriguez-Bellido, Cesar Pastor-Asurza, et al.

    Aim: To evaluate the factors associated with changes in self-efficacy in systemic lupus erythematosus (SLE) patients from a prevalent cohort. Methods: Members of the Almenara Lupus Cohort who had entered it between 2018 and 2024 were included. Sociodemographic variables were collected. Self-efficacy was examined with the five domains of the PROMIS self-efficacy for the management of chronic conditions’ instrument and general self-efficacy. The Short Form (SF)-36 health questionnaire’ [physical and mental component summary measures (PCS and MCS)] was obtained. Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and damage with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Therapeutic variables included the use of antimalarials and of immunosuppressants as well as the daily prednisone dose. Generalized estimating equations were performed using general self-efficacy and the five domains for chronic disease management as outcomes. Results: 331 patients were included; their mean age at diagnosis was 35.1 (SD = 13.7) years and 91.5% their disease duration at baseline was 10.3 (SD = 7.49) years; ( n = 303) were women; 97.9% were Mestizo. Factors associated with a better general self-efficacy were White ethnicity (β = 7.09, SE = 1.14, p < 0.001), being currently employed (β = 1.09, SE = 0.53, p = 0.038), PCS (β = 0.08, SE = 0.02, p < 0.001), and previous general self-efficacy (β = 0.39, SE = 0.05, p < 0.001). In contrast, Black ethnicity (β = −2.06, SE = 0.56, p < 0.001 and daily prednisone dose (β = −0.13, SE = 0.02, p < 0.001) were negatively associated with general self-efficacy. Conclusions: Factors associated with general self-efficacy improvement were higher previous self-efficacy, White ethnicity, being currently employed and having a better HRQoL In contrast, Black ethnicity and higher daily prednisone dose predisposed to general self-efficacy worsening.

  • Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort

    by Rosana Quintana, Guillermo J. Pons-Estel, Daniel Wojdyla, Graciela S. Alarcón, Rosa María Serrano, Manuel Ugarte-Gil, Víctor Pimentel-Quiroz, Luis J. Catoggio, Marina Scolnik, Mónica Sacnun, et al.

    Objective: To assess the effect of antimalarials (AMs) on overall damage and on its most frequently affected domains, as measured by the Systemic Lupus International Collaborating Clinics Damage Index (SDI) in patients from the GLADEL cohort. Methods: New damage was defined as a ≥1 point increase in SDI since cohort entry. AMs users were those who received AMs for at least 6 months after entering the cohort. AMs users and non-users were matched for age, sex, ethnicity, and baseline SDI using stratified random sampling. Two comparisons were carried out: patients with and without new damage, and AM users versus non-users. Propensity score matching was used to determine the effect of AM use on the most frequently affected damage domains. Results: A total of 850 patients were included; 419 (49.3%) were AM users and 431 (50.7%) non-users. During a median follow-up of 48.5 (IQR 19.3, 69.0) months, 472 (55.5%) developed damage. The most affected domains were skin (18.4%), renal (14.6%), neuropsychiatric (10.8%), musculoskeletal (6.9%), and cardiovascular (4.5%). AMs use was associated with a lower proportion of patients accruing damage at follow-up (170 [40.6%] vs 208 [48.3%]; p = .028). AMs were protective against overall damage (HR 0.7, 95% CI [0.5–0.9]; p = .002), renal (HR 0.4, 95% CI [0.3–0.6]; p < .001), and neuropsychiatric damage (HR 0.5, 95% CI [0.3–0.9]; p = .022). Conclusion: AM use is independently associated with a lower probability of overall, renal, and neuropsychiatric damage accrual. These findings support early and sustained AM treatment in lupus patients, unless contraindicated.

  • Open Access

    Systemic Lupus International Collaborating Clinics Frailty Index predicts mortality in systemic lupus erythematosus patients: data from the Almenara Lupus Cohort

    by Benny Harold Rashuamán-Conche, Rocio Violeta Gamboa-Cárdenas, Victor Román Pimentel-Quiroz, Anubhav Singh, Cristina Reátegui-Sokolova, Claudia Elera-Fitzcarrald, Samira Garcia-Hirsh, Cesar Pastor-Asurza, Zoila Rodríguez-Bellido, Risto Alfredo Perich-Campos, et al.

    Objective: Frailty has been shown to predict damage accrual in patients with systemic lupus erythematosus (SLE), including those from Latin America. However, the impact of frailty on mortality has been scarcely evaluated, particularly in Latin American populations. The aim of this study was to evaluate frailty as a predictor of mortality in Latin American SLE patients. Methods: Patients from a single-centre 2012–2025 prevalent cohort were studied. Mortality was defined as the vital status according to the Peruvian Department of Health. Frailty was ascertained using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a continuous variable. Univariable and multivariable Cox regression models were done to estimate its impact on mortality. Multivariable models were adjusted for possible confounders. Sensitivity analyses were performed including data up to March 2020 to avoid the potential influence of the COVID-19 pandemic. Additionally, a Kaplan-Meier curve was calculated by frail status (frail, SLICC-FI >0.21; non-frail, SLICC-FI ≤0.21). Results: Four hundred and ninety-five patients were included, 456 (92.1%) were women and 96 (19.4%) were frail. Their mean (SD) age at diagnosis was 35.0 (14.0) years, their mean disease duration at baseline was 6.7 (6.1) years and their mean follow-up time was 8.5 (4.2) years. Fifty-six (11.3%) patients died during the follow-up. The SLICC-FI predicted mortality even after adjusting for possible confounders (hazard ratio (HR)=1.54 (CI 95% 1.11 to 2.14), p=0.010). This prediction capability remained on the sensitivity analyses (HR 1.85; (95% CI 1.30 to 2.61), p<0.001). Conclusion: Frailty, as ascertained with the SLICC-FI, was a predictor of mortality in a Latin American cohort of SLE patients. Frailty could be considered in the monitoring of SLE patients; possible interventions to modify it should be developed.

  • Open Access

    Systemic Lupus International Collaborating Clinics-Frailty Index predicts hospitalisations in the Almenara Lupus Cohort

    by Anubhav Singh, Rocio Violeta Gamboa-Cárdenas, Victor Román Pimentel-Quiroz, Cristina Reátegui-Sokolova, Zoila Rodriguez-Bellido, Cesar Augusto Pastor-Asurza, Risto Alfredo Perich-Campos, Graciela S Alarcón, Manuel Francisco Ugarte-Gil

    Objectives: To evaluate the Systemic Lupus International Collaborating Clinics-Frailty Index (SLICC-FI) as a predictor of hospitalisations in patients with SLE from a Latin American cohort. Methods: Patients from a single-centre prevalent cohort were included. The SLICC-FI was assessed at baseline. Hospitalisations, their number as well as their duration (in days), were reported during the first 3 years from the baseline visit. Univariable and multivariable negative binomial regressions were performed to determine the association between the baseline SLICC-FI (per 0.05 increase) and hospitalisations during follow-up (number and length), adjusted for possible confounders. An alternative analysis was carried out after excluding the damage-related deficits, rendering a modified SLICC-FI. Results: Of the 295 patients included, 273 (92.5%) were female, with a mean (SD) age at diagnosis of 34.8 (13.5) years. At baseline, the mean SLICC-FI was 0.18 (0.05) with 86 (29.2%) patients categorised as being frail. The mean number of hospitalisations per patient-year was 0.4 (0.8) and the mean number of days hospitalised during the 3-year period per patient-year was 3.1 (7.6) days. The SLICC-FI predicted a higher number and days of hospitalisations (incidence rate ratio (IRR): 1.671 (95% CI: 1.385 to 2.016) and IRR: 2.018 (95% CI: 1.715 to 2.375), respectively). The modified SLICC-FI also predicted hospitalisations in both number and days. Conclusion: The SLICC-FI predicted hospitalisations in patients with SLE, independent of other well-known risk factors. Further studies are needed to develop strategies to improve frailty in these patients.


  • Systemic Lupus International Collaborating Clinics Frailty Index Predicts Worsening Health‐Related Quality of Life, Data From the Almenara Lupus Cohort

    by Anubhav Singh, Rocío V. Gamboa‐Cárdenas, Victor Pimentel‐Quiroz, Zoila Rodriguez‐Bellido, Cesar Pastor‐Asurza, Risto Perich‐Campos, Graciela S. Alarcón, Manuel Francisco Ugarte‐Gil

    Objective: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC‐FI) as a predictor of quality of life (QoL) in patients with systemic lupus erythematosus (SLE) has not been evaluated longitudinally. We estimated the association of SLICC‐FI scores with future QoL in our prevalent Latin American Mestizo cohort.Methods: Patients from a single‐center SLE cohort were included. Health‐related QoL was ascertained with the LupusQoL tool, and frailty was ascertained with the SLICC‐FI. Generalized estimating equations were performed, using each domain of the LupusQoL as an outcome in the subsequent visit, and the SLICC‐FI (as a continuous variable) in the previous visit. Alternative analyses were also conducted including the SLICC‐FI as a categorical variable. In both approaches, the multivariable models were adjusted for possible confounders (age at diagnosis, sex, socioeconomic status, ethnicity, Systemic Lupus Erythematosus Disease Activity Index 2000, SLICC/American College of Rheumatology damage index [SDI], disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drug treatment, and the same domain of the LupusQoL in the previous visit).Results: A total of 428 patients and 2,645 visits were included in this study, and they were observed for 4.71 ± 3.52 years. At baseline, the mean ± SD of disease duration, SDI scores, and SLICC‐FI scores were 7.2 ± 6.6 years, 1.0 ± 1.3, and 0.17 ± 0.05, respectively.In the main analysis, after adjusting for possible confounders, higher SLICC‐FI scores predicted a higher LupusQoL score in the domains of pain, planning, emotional health, and fatigue. In the alternative analyses, after adjustment, the frail and least fit categories were predictive of higher LupusQoL scores in the domain of fatigue, and frailty (SLICC‐FI score of >0.21) predicted worse body image compared with least fit (SLICC‐FI score 0.03–0.10).Conclusion: Higher SLICC‐FI scores predicted worse health‐related QoL as measured by higher LupusQoL scores from patients from the Almenara lupus cohort. Our findings reinforce the prognostic value of this tool in patients with SLE. image


  • Validation of the ANCA-Associated Vasculitis Patient-Reported Outcomes Questionnaire in a Latin American Vasculitis Cohort

    by Victor R. Pimentel-Quiroz, Rocío V. Md Gamboa-Cárdenas, Zoila Rodríguez-Bellido, Risto Md Perich-Campos, Graciela S. Alarcón, Manuel F. Ugarte-Gil

    Background/Objectives: The aim of this work is to validate the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire in a Latin American (Peru) AAV cohort. Methods: We included patients from the Almenara vasculitis cohort who had at least 1 visit between December 2022 and June 2024. Sociodemographic features, disease activity (Birmingham Vasculitis Activity Score version 3 [BVASv3] score), damage (Vasculitis Damage Index [VDI] score), the AAV-PRO (Spanish version), and the Short Form 36 (SF-36) were obtained. The AAV-PRO includes 6 domains (organ-specific symptoms, systemic symptoms, treatment side effects, social and emotional impact, concerns about the future, and physical function); the score ranges from 0 to 100: the higher the value, the worse the health-related quality of life. Correlations between domains of the AAV-PRO and clinical and sociodemographic variables were evaluated using Spearman correlation. Results: Eighty-two patients were included; 60 (73.2%) of them were female. Their age and disease duration were 55.3 (14.3) and 5.7 (5.2) years, respectively. The BVASv3 and the VDI scores were 6.1 (9.0) and 2.4 (1.7), respectively. Overall, every domain of the AAV-PRO correlated strongly and inversely with the global scores of the SF-36 (physical component summary and mental component summary) (all r < −0.4 and p < 0.001). Physical function, role physical, role emotional, and physical component summary correlated inversely with the BVASv3, whereas the organ-specific symptoms score correlated positively with the VDI. Conclusions: The Spanish version of the AAV-PRO questionnaire correlated with the SF-36 in AAV patients from a Peruvian cohort. These findings may support the use of this instrument in other Latin American populations.


  • Hypertension is associated with global and renal damage accrual in patients with systemic lupus erythematosus. Data from the Almenara Lupus Cohort

    by Fernando Piero Díaz-Ramírez, Fiorella Vanessa Saldaña-Alvarado, Rocío V. Gamboa-Cárdenas, Victor Pimentel-Quiroz, Cristina Reategui-Sokolova, Claudia Elera-Fitzcarrald, Erika Noriega, Zoila Rodriguez-Bellido, Cesar Pastor-Asurza, Risto Perich-Campos, et al.

    Objectives: To determine the association between the occurrence of hypertension and damage accrual in patients with systemic lupus erythematosus (SLE). Materials and methods: From January 2012 to January 2020, we evaluated 314 SLE patients, all members of the Almenara Lupus Cohort. We applied the American College of Cardiology/American Heart Association (ACC/AHA) guidelines to define hypertension, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) to determine organ damage, and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) to assess disease activity. We performed univariable and multivariable analysis using generalized estimating equations, adjusting for potential confounders (demographic factors, disease-related factors and treatment). Results: 314 patients and 1695 visits were included; 93% of the patients were women. Their mean disease duration was of 6.8 years (SD: 6.4), and their age at diagnosis of 35.7 (SD: 13.4) years. Baseline damage was 0.8 (SD: 1.2) at the first visit, increasing by 0.15 points at the subsequent follow-up visit (SD: 0.46). The prevalence of hypertension in these patients was 56.4% at least once during their follow-up. In the multivariable analysis, hypertension remained associated with damage accrual (IRR: 1.645, 95% CI: 1.187–2.280, p = 0.003) after adjusting for confounders. In the analyses performed per domain, hypertension was associated with renal damage in the multivariable model (OR: 4.331, 95% CI 1.547–12.126, p = 0.005). Conclusion: Hypertension was associated with subsequent greater damage in our SLE patients. Thus, providers involved on the care of these patients should monitor their blood pressure at all clinic visits.